Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies

This original research investigates the critical issue of gastrointestinal (GI) second primary malignancies (SPMs) in patients with signet ring cell carcinoma (SRCC), a rare and aggressive subtype of colorectal cancer. Utilizing the Surveillance, Epidemiology, and End Results (SEER) database, the investigators assessed the risk of GI SPMs, particularly within 2-11 months post-SRCC diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Carcinoma Adenocarcinoma Cancer Carcinoma Carcinoma, Signet Ring Cell Colonic Diseases Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Cystic, Mucinous, and Serous Neoplasms, Glandular and Epithelial Rectal Diseases Signet Ring Adenocarcinoma of the Colon

Sex eligibility

All sexes

Study type

Observational

Primary location

Suez Canal University

Ismailia, 41512, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients diagnosed with primary colorectal SRCC between 2000 and 2021
Latency exclusion period of two months

Exclusion criteria

patients with unknown age data

Treatment and study plan

Primary outcomes

The standardized incidence ratio of developing gastrointestinal second primary malignancies following primary colorectal signet ring cell carcinoma

Time frame: from Jan, 2000 till Dec, 2021

The surveillance, epidemiology and End Results (SEER) database was used to calculate the standardized incidence ratio (SIR) as Observed/Expected (O/E) for second primary gastrointestinal malignancies. Patients diagnosed with primary colorectal SRCC between 2000 and 2021 were included. The event was defined as the appearance of an SPM in a different site from the original cancer at a new GI organ (esophagus, stomach, small intestine, cecum, appendix, rectum, anus and anal canal, liver, gallbladder, intrahepatic bile duct, pancreas, retro-peritoneum, and colon).

Secondary outcomes

The excess risk of developing gastrointestinal second primary malignancies following primary colorectal signet ring cell carcinoma

Time frame: from Jan, 2000 till Dec, 2021

The excess risk per 10,000 was calculated using SEER*stat software.

Sponsors and collaborators

Lead sponsor

asmaa salama ibrahim

Other

Registry information

Official study title

Primary Colorectal Signet Ring Cell Carcinoma and the Risk of Multiple Primary Gastrointestinal Malignancies: a Retrospective Cohort Based on SEER Database From 2000-2021

Important dates

Study start: 2000
Primary completion: 2021
Study completion: 2021
First posted: May 18, 2025
Registry last updated: May 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed